Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8958766 | 1.00 | BCHE (0.54) | BCHENR1I2S1PR1S1PR3S1PR5 | |
| SCHEMBL16618489 | 0.98 | BCHE (0.56) | BCHENR1I2S1PR1S1PR3S1PR5 | |
| SCHEMBL10983481 | 0.98 | BCHE (0.56) | BCHENR1I2S1PR1S1PR3S1PR5 | |
| SCHEMBL8501215 | 0.98 | BCHE (0.56) | BCHENR1I2S1PR1S1PR3S1PR5 | |
| Hydrochloric Acid SCHEMBL7769067 | 0.97 | BCHE (0.55) | BCHENR1I2S1PR1S1PR3S1PR5 | |
| SCHEMBL3231146 | 0.95 | SMN1; SMN2 (0.49) | BCHENR1I2S1PR1S1PR3S1PR5 | |
| SCHEMBL7278054 | 0.95 | NR1I2 (0.53) | BCHENR1I2S1PR1S1PR3S1PR5 | |
| SCHEMBL15664773 | 0.95 | NR1I2 (0.53) | BCHENR1I2S1PR1S1PR3S1PR5 | |
| SCHEMBL27522848 | 0.94 | BCHE (0.51) | BCHENR1I2S1PR1S1PR3S1PR5 | |
| Hydrochloric Acid SCHEMBL27415879 | 0.93 | NR1I2 (0.52) | BCHENR1I2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124569-A1 | MACROCYCLIC COMPOUNDS, PROTEASE INHIBITION, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-05-26 | — | — | US | claimed |
| EP-0692470-A1 | Process for the preparation of optically active 1-substituted-2-(aminomethyl)pyrrolidine derivatives | Degussa Aktiengesellschaft (DE) | 1996-01-17 | — | — | EP | claimed |
| JP-8169877-A | — | — | None | — | — | JP | disclosed |
| JP-H08169877-A | PRODUCTION OF OPTICALLY ACTIVE 1-SUBSTITUTED 2-(AMINOMETHYL)PYRROLIDINE | DEGUSSA AG | 1996-07-02 | — | — | JP | disclosed |
| EP-0692470-A1 | Process for the preparation of optically active 1-substituted-2-(aminomethyl)pyrrolidine derivatives | Degussa Aktiengesellschaft (DE) | 1996-01-17 | — | — | EP | disclosed |
| EP-0692470-A1 | Process for the preparation of optically active 1-substituted-2-(aminomethyl)pyrrolidine derivatives | Degussa Aktiengesellschaft (DE) | 1996-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124569-A1 | MACROCYCLIC COMPOUNDS, PROTEASE INHIBITION, AND METHODS OF TREATMENT | PREP, SERPINB1, CTSC | BCHE 417/4885NR1I2 4003/4885S1PR1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.